Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Elizabeth Robins Gerstner, M.D.

Co-Author

This page shows the publications co-authored by Elizabeth Gerstner and Rakesh Jain.
Connection Strength

3.293
  1. Vascular dysfunction promotes regional hypoxia after bevacizumab therapy in recurrent glioblastoma patients. Neurooncol Adv. 2020 Jan-Dec; 2(1):vdaa157.
    View in: PubMed
    Score: 0.233
  2. Bevacizumab Reduces Permeability and Concurrent Temozolomide Delivery in a Subset of Patients with Recurrent Glioblastoma. Clin Cancer Res. 2020 01 01; 26(1):206-212.
    View in: PubMed
    Score: 0.215
  3. Publisher Correction: Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI. Sci Rep. 2019 Jun 14; 9(1):8721.
    View in: PubMed
    Score: 0.211
  4. Solid stress in brain tumours causes neuronal loss and neurological dysfunction and can be reversed by lithium. Nat Biomed Eng. 2019 03; 3(3):230-245.
    View in: PubMed
    Score: 0.205
  5. Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI. Sci Rep. 2018 11 20; 8(1):17062.
    View in: PubMed
    Score: 0.203
  6. Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma. J Neurooncol. 2017 02; 131(3):603-610.
    View in: PubMed
    Score: 0.176
  7. A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma. Neuro Oncol. 2015 Oct; 17(10):1386-92.
    View in: PubMed
    Score: 0.159
  8. Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma. J Clin Oncol. 2015 Apr 01; 33(10):1197-213.
    View in: PubMed
    Score: 0.157
  9. Vessel caliber--a potential MRI biomarker of tumour response in clinical trials. Nat Rev Clin Oncol. 2014 Oct; 11(10):566-84.
    View in: PubMed
    Score: 0.151
  10. Increased perfusion due to vascular normalization improves oxygenation and survival in glioblastoma patients treated with cediranib with or without chemoradiation. Neuro Oncol. 2014 Jul; 16 Suppl 3:iii12.
    View in: PubMed
    Score: 0.150
  11. Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation. Oncologist. 2014 Jan; 19(1):75-81.
    View in: PubMed
    Score: 0.144
  12. Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci U S A. 2013 Nov 19; 110(47):19059-64.
    View in: PubMed
    Score: 0.143
  13. Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma. Neuro Oncol. 2013 Aug; 15(8):1079-87.
    View in: PubMed
    Score: 0.140
  14. Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide. J Neurooncol. 2011 Jun; 103(2):325-32.
    View in: PubMed
    Score: 0.115
  15. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol. 2010 Jun 10; 28(17):2817-23.
    View in: PubMed
    Score: 0.112
  16. Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib. Neuro Oncol. 2010 May; 12(5):466-72.
    View in: PubMed
    Score: 0.110
  17. Anti-vascular endothelial growth factor therapy for malignant glioma. Curr Neurol Neurosci Rep. 2009 May; 9(3):254-62.
    View in: PubMed
    Score: 0.105
  18. VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer. Nat Rev Clin Oncol. 2009 Apr; 6(4):229-36.
    View in: PubMed
    Score: 0.104
  19. Advances in neuroimaging techniques for the evaluation of tumor growth, vascular permeability, and angiogenesis in gliomas. Curr Opin Neurol. 2008 Dec; 21(6):728-35.
    View in: PubMed
    Score: 0.102
  20. Antiangiogenic agents for the treatment of glioblastoma. Expert Opin Investig Drugs. 2007 Dec; 16(12):1895-908.
    View in: PubMed
    Score: 0.095
  21. A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases. Breast Cancer Res Treat. 2020 Jan; 179(1):113-123.
    View in: PubMed
    Score: 0.054
  22. Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade Glioma. Clin Cancer Res. 2018 10 01; 24(19):4643-4649.
    View in: PubMed
    Score: 0.049
  23. Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma. Cancer. 2018 04 01; 124(7):1438-1448.
    View in: PubMed
    Score: 0.048
  24. Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival. NPJ Precis Oncol. 2017; 1.
    View in: PubMed
    Score: 0.046
  25. Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas. J Clin Oncol. 2016 05 10; 34(14):1669-75.
    View in: PubMed
    Score: 0.042
  26. Phase Ib study of cediranib in combination with daily temozolomide and radiation in patients with newly diagnosed glioblastoma. J Clin Oncol. 2009 May 20; 27(15_suppl):e13010.
    View in: PubMed
    Score: 0.026
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.